Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03113188 · ClinicalTrials.gov registry record · Phase 1
CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors
A Phase 1 study, sponsored by CanBas Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT03113188 is a Phase 1 study that has completed, run by CanBas Co.. The registered enrollment target is 47 participants.
The verdict
NCT03113188, a Phase 1 study, has completed, sponsored by CanBas Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, phase 1b study of CBP501/cisplatin/nivolumab combination administered once every 21 days to patients with advanced solid tumors.
Interventions
- DRUG CBP501
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2017-10-25 |
| Est. Completion | 2021-02-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03113188
The ClinicalTrials.gov registry entry for NCT03113188 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CanBas Co., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CBP501 is the first listed.
NCT03113188 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03113188 about?
NCT03113188 is a clinical study titled "CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors". This is a multicenter, open-label, phase 1b study of CBP501/cisplatin/nivolumab combination administered once every 21 days to patients with advanced solid tumors.
What is the current status of trial NCT03113188?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2017-10-25. Estimated completion is 2021-02-15.
What interventions are being tested in trial NCT03113188?
The interventions under investigation include: CBP501 (DRUG).
Who is sponsoring clinical trial NCT03113188?
This trial is sponsored by CanBas Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.